The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

China has one of the largest populations with obesity in the world, and obesity has become
a major challenge for the country's health-care system. Current guidelines for obesity …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Background French national health care insurance system database has suggested 1–3
years use of glucagon like peptide-1 receptor agonists (GLP1RA)(exenatide, liraglutide and …

Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …

The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes
(T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists …

The 21st century is characterized by an increasing incidence and prevalence of obesity and
the burden of its associated comorbidities, especially cardiometabolic diseases, which are …

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as
promising therapeutic options for addressing Type‐2 diabetes, obesity, and related …

OBJECTIVE We conducted a randomized, double-blind, placebo-controlled phase 2 trial to
evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and …